Clinical Trial

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
Protocol Amendment History 3 changes
notable Trial sites expanded: 40 -> 43 locations 2026-07-03
critical Recruitment opened 2026-06-12
notable Trial sites expanded: 0 -> 40 locations 2026-06-12
Trial Details
NCT Number NCT07575399
Lead Sponsor Amgen
Conditions Obesity or Overweight
Enrollment 300 participants
Start Date 2026-05-11
Primary Completion 2028-01-03 (estimated)
Study Completion 2028-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-02